ABOS - Acumen Pharmaceuticals, Inc.
2.26
-0.290 -12.832%
Share volume: 919,327
Last Updated: 03-27-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
-0.04%
PREVIOUS CLOSE
CHG
CHG%
$2.55
-0.29
-0.11%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-14-2024 | 08-13-2024 | 11-12-2024 | 03-27-2025 | 05-13-2025 | 11-12-2025 | 03-26-2026 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | ||||
| Operating expenses | 17.774 M | 24.381 M | 32.265 M | 39.597 M | 30.370 M | 26.513 M | 25.199 M | |
| Selling general and admin | 5.325 M | 4.848 M | 5.018 M | 5.028 M | 5.104 M | 4.545 M | 4.673 M | |
| Research and development | 12.449 M | 19.533 M | 27.247 M | 34.569 M | 25.266 M | 21.968 M | 20.526 M | |
| Total expenses | 17.774 M | 24.381 M | 32.265 M | 39.597 M | 30.370 M | 26.513 M | 25.199 M | |
| 37.17% | 32.34% | 22.72% | -23.30% | -12.70% | -4.96% | |||
| Operating income | -17.774 M | -24.381 M | -32.265 M | -39.597 M | -30.370 M | -26.513 M | -25.199 M | |
| Ebit | -17.878 M | -23.349 M | -32.242 M | -39.109 M | -30.244 M | -27.022 M | -25.373 M | |
| Pretax income | -14.873 M | -20.537 M | -29.765 M | -37.154 M | -28.796 M | -26.451 M | -25.138 M | |
| 38.08% | 44.93% | 24.82% | -22.50% | -8.14% | -4.96% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -14.873 M | -20.537 M | -29.765 M | -37.154 M | -28.796 M | -26.451 M | -25.138 M | |
| -38.08% | -44.93% | -24.82% | 22.50% | 8.14% | 4.96% |